Zacks Investment Research upgraded shares of Aeglea Biotherapeutics Inc. (NASDAQ:AGLE) from a sell rating to a hold rating in a research report released on Tuesday morning.
According to Zacks, “Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. “
Aeglea Biotherapeutics (NASDAQ:AGLE) opened at 6.90 on Tuesday. The firm’s 50-day moving average price is $6.67 and its 200-day moving average price is $6.59. The company’s market cap is $92.54 million. Aeglea Biotherapeutics has a 1-year low of $3.89 and a 1-year high of $12.75.
Aeglea Biotherapeutics (NASDAQ:AGLE) last posted its earnings results on Tuesday, August 9th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.03. Equities research analysts forecast that Aeglea Biotherapeutics will post ($4.77) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Ghost Tree Capital LLC purchased a new position in Aeglea Biotherapeutics during the second quarter worth $243,000. Perceptive Advisors LLC purchased a new position in Aeglea Biotherapeutics during the second quarter worth $515,000. Finally, VHCP Management II LLC purchased a new position in Aeglea Biotherapeutics during the second quarter worth $1,527,000. Institutional investors and hedge funds own 40.71% of the company’s stock.
About Aeglea Biotherapeutics
Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.